# Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

> **NCT03315364** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Daehwa Pharmaceutical Co., Ltd.** · enrollment: 549 (actual)

## Conditions studied

- Recurrent or Metastatic Breast Cancer

## Interventions

- **DRUG:** Oral paclitaxel
- **DRUG:** Paclitaxel injection

## Key facts

- **NCT ID:** NCT03315364
- **Lead sponsor:** Daehwa Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-18
- **Primary completion:** 2024-02-19
- **Final completion:** 2028-11-30
- **Target enrollment:** 549 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315364, "Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03315364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*